ADCC-Enhanced Anti-Human CD20 (Mosunetuzumab) Antibody (CAT#: BioBet-CB-088LX) Datasheet

CD20

Membrane spanning 4-domains A1

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein. [provided by RefSeq, Jul 2008]

B1; S7; Bp35; CD20; FMC7; CVID5; MS4A2; LEU-16

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Mosunetuzumab

Humanized

Human

ADCC-Enhanced Anti-Human CD20 (Mosunetuzumab) Antibody is derived from clone Mosunetuzumab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD20, and it is intended for the research of Follicular lymphoma .

Follicular lymphoma

Similar to the parental antibody Mosunetuzumab, ADCC-Enhanced Anti-Human CD20 (Mosunetuzumab) Antibody targets to the antigen CD20, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.